Elanco Animal Health Stock Price, News & Analysis

Elanco Animal Health (NYSE: ELAN) has received FDA approval for Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), the broadest canine oral parasiticide, offering protection against six parasites: fleas, ticks, heartworms, roundworms, hookworms, and tapeworms. This product is the first to combine four active ingredients in a single, monthly chewable tablet for dogs aged eight weeks and older. Credelio Quattro starts killing ticks and fleas within 4 hours, achieving over 99% flea kill within 8 hours and 100% within the first day, remaining effective for a month. It provides 100% protection against heartworm disease from the first dose and is effective against zoonotic parasites, which can infect both pets and humans. Elanco plans to launch Credelio Quattro in Q1 2025, joining its existing portfolio of parasiticides, including Seresto® and Advantage®.

Elanco Animal Health (NYSE: ELAN) announced FDA approval and launch of Zenrelia™ (ilunocitinib tablets), a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitis. Zenrelia enters the estimated $1.7 billion global canine dermatology market, offering an effective solution for controlling pruritus in dogs at least 12 months old.

In a head-to-head study, Zenrelia was shown to be at least as effective as the market incumbent JAK inhibitor, with 77% of Zenrelia-treated dogs achieving clinical remission of itch, compared to 53% treated with Apoquel®. Zenrelia's launch price is about 20% less for nearly all dogs compared to the current JAK inhibitor, making it more affordable for pet owners.

The approval represents Elanco's first entry into the fast-growing canine dermatology market, expanding their comprehensive portfolio for veterinarians.

Elanco recently explored the challenges and motivations of veterinarians through interviews with Dr. Emily Swiniarski and Dr. Amanda Schnitker. The discussion highlighted the complex reality of veterinary medicine, where professionals enter the field for their love of animals but find their work heavily involves managing pet owners' emotions and expectations. Key issues facing veterinarians include:

1. Ongoing impacts of the COVID-19 pandemic
2. Compassion fatigue
3. Shortage of veterinarians and technical staff
4. Visit decline due to new competitive care models

Despite these challenges, veterinarians find fulfillment in providing care and connecting with animals and their owners. Elanco supports veterinarians by offering business expertise and innovative solutions for unmet needs in animal health.

Elanco Animal Health (NYSE: ELAN) has provided an update on its contract manufacturing partner, TriRx Speke , which has entered into trading administration in the UK. Elanco has a long-term supply agreement with TriRx for select farm animal products. The company is working with administrators to ensure business continuity and explore options. Elanco expects minimal supply disruption in 2024 and is underwriting operational costs to maintain production and employee payments in the interim.

Despite an anticipated reduction of $5 million to $10 million in adjusted EBITDA for 2024 due to the TriRx situation, Elanco maintains its full-year adjusted EBITDA guidance of $900 million to $940 million.

Elanco Animal Health (NYSE: ELAN) announces its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference, scheduled for September 4-5, 2024. The company's President and CEO Jeff Simmons, along with Executive VP and CFO Todd Young, will engage in a fireside chat on Thursday, September 5 at 3:20 p.m. ET.

Investors and interested parties can access a live audio webcast of the session through the "Events and Presentations" section of Elanco's investor website. For those unable to attend live, a replay will be available for approximately 30 days after the event. This conference participation highlights Elanco's commitment to investor relations and provides an opportunity for stakeholders to gain insights into the company's strategies and performance.

Elanco Animal Health Incorporated (NYSE: ELAN) announced that its broad-spectrum parasiticide, Credelio Quattro, has entered the final 60-day FDA administrative review. The company expects U.S. approval in October and plans to launch the product in Q1 2025. Elanco is seeking approval for indications that would provide the broadest parasite coverage, including fleas, ticks, heartworms, and tapeworms.

CEO Jeff Simmons highlighted Elanco's robust innovation portfolio, projecting $600 million to $700 million in innovation sales for 2025. The company is finalizing manufacturing scale-up to optimize the launch. This development follows the completion of Bovaer's review ahead of schedule, with both Zenrelia and Credelio Quattro now in final FDA review, demonstrating Elanco's R&D capabilities.

Elanco's CEO Jeff Simmons launches the Shared Table LinkedIn Newsletter, focusing on conversations about leadership, purpose, animals, and improving life. The first edition features a discussion with Dr. Frank Mitloehner, Director of the UC Davis CLEAR Center, on livestock sustainability and climate change.

Key points include:

• The potential for climate-neutral animal agriculture within this decade
• The importance of reducing methane to mitigate global warming
• Introduction of Bovaer, a methane-reducing feed ingredient for dairy cattle
• The dairy industry's opportunity to impact methane emissions significantly
• The need for sustainability solutions that provide both economic and environmental benefits

The conversation highlights the $1-2 billion market potential in animal health for livestock sustainability solutions.

A recent study published in Parasites & Vectors demonstrates that Credelio, an Elanco Animal Health product, outperforms competitors in tick protection for dogs. The study compared Credelio (lotilaner) with Simparica TRIO (sarolaner, moxidectin, pyrantel) and NexGard (afoxolaner) against the aggressive lone star tick. Key findings include:

1. Credelio kills ticks 2x faster than competitors, achieving significant tick reduction within 12 hours.
2. Credelio maintains rapid tick-killing efficacy throughout the entire month-long treatment period.
3. Only Credelio showed significant tick reduction compared to the untreated control group at all 12-hour evaluation intervals.

This study is particularly relevant as the CDC reported over 45,000 human cases of tickborne diseases from 2019-2022. Credelio's superior performance in rapidly killing ticks could help reduce the risk of pathogen transmission to both pets and humans.

Elanco Animal Health (NYSE: ELAN) reported Q2 2024 results with revenue of $1,184 million, a 12% increase. The company saw a net loss of $50 million and adjusted net income of $147 million. Adjusted EBITDA stood at $275 million, 23.2% of revenue, while adjusted EPS was $0.30.

Elanco raised its full-year revenue guidance to $4,410-$4,460 million, reflecting 3-4% organic constant currency growth. The net income forecast is $314-$352 million, with adjusted EPS at $0.88-$0.96. The company completed the sale of its aqua business, reducing debt by $1.3 billion.

Key products like Experior, Adtab, and Credelio Plus contributed to growth. FDA approvals for Bovaer and the pending approval for Zenrelia are expected to boost future revenues. Pet Health revenue rose 12% to $579 million, while Farm Animal revenue increased 13% to $594 million. Gross profit was $689 million, 58.2% of revenue. Elanco projects $1.02-$1.05 billion in Q3 2024 revenue and $0.09-$0.14 in adjusted EPS.